Multifocal glioblastoma-two case reports and literature review.

Chin Neurosurg J

Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, No.183 Xinqiao Street, Shapingba District, Chongqing City, 400037, People's Republic of China.

Published: January 2021

Background: Multifocal glioblastoma is a rare type of glioblastoma with worse prognosis. In this article, we aimed to report two cases of classical multifocal glioblastoma.

Case Presentation: In case 1, a 47-year-old male presented with dizziness, and once had a sudden loss of consciousness accompanied by convulsion of limbs. Contrast-enhanced MRI showed multiple lesions with heterogeneously ring-enhanced characters in the left hemisphere, diagnosed as multifocal glioblastoma. He underwent a craniotomy of all lesions, concurrent radiotherapy and chemotherapy as well as additional chemotherapy of temozolomide. After 2 cycles, repeat MRI showed that the new lesions already occurred and progressed. Eventually, he abandoned the chemotherapy after the 2 cycles and died 1 year later. In case 2, a 71-year-old male presented with a history of headache, left limb weakness, and numbness. Discontinuous convulsion of limbs once occurred. Contrast-enhanced MRI showed multiple lesions located in the right hemisphere, diagnosed as multifocal glioblastoma. He underwent a right frontoparietal craniotomy of the main lesion. Hemorrhage of the residual tumor and pulmonary artery embolism occurred synchronously. Eventually, his family decided not to pursue any further treatment and opted for hospice care and he passed away within 11 days of surgery.

Conclusions: We reported two cases of typical multifocal glioblastoma. Valid diagnosis is crucial; then, resection of multiple lesions and canonical radio-chemotherapy probably bring survival benefits.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809824PMC
http://dx.doi.org/10.1186/s41016-020-00223-zDOI Listing

Publication Analysis

Top Keywords

multifocal glioblastoma
16
multiple lesions
12
male presented
8
convulsion limbs
8
contrast-enhanced mri
8
mri multiple
8
hemisphere diagnosed
8
diagnosed multifocal
8
glioblastoma underwent
8
multifocal
6

Similar Publications

Article Synopsis
  • The study investigates how multimodal treatment affects progression-free survival (PFS) and overall survival (OS) for patients with multiple localizations of glioblastoma, a rare and aggressive brain tumor.* -
  • Researchers analyzed data from 483 glioblastoma patients, finding that the extent of surgical resection significantly predicts both PFS and OS, and that various treatment strategies improved outcomes.* -
  • The results indicate that patients with multiple lesions can achieve similar survival rates as those with a single tumor when receiving aggressive, comprehensive treatment.*
View Article and Find Full Text PDF

A novel scoring system proposal to guide surgical treatment indications for high grade gliomas in elderly patients: DAK-75.

Neurosurg Rev

October 2024

Neurosurgery Unit, "Città Della Salute E Della Scienza" University Hospital, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10124, Turin, Italy.

High-grade gliomas are the most prevalent neurooncological desease in adults, their incidence increases with age, peaking in the seventh decade. This paper aims to address how to select patients for surgical resection by identifying pre-surgical predictors of 12-month mortality in newly diagnosed HGG patients aged ≥ 75 years. A prognostic score will be proposed to guide surgical decisions based on expected survival.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the effectiveness of a new index called GINI in predicting outcomes for patients with grade 4 adult-type diffuse gliomas, comparing it to established indices like SII, SIRI, and PIV.
  • - In their analysis of 198 patients, those with a high GINI value (<5815) had significantly poorer overall survival (OS) and progression-free survival (PFS) compared to those with a low GINI value, with high GINI being linked to older age and worse overall health status.
  • - The research concluded that GINI is a strong prognostic tool for assessing patient outcomes in specific types of brain tumors, demonstrating greater predictive power than the other indices studied.
View Article and Find Full Text PDF

Introduction: There are no guidelines or prospective studies defining the optimal surgical treatment for glioblastomas in older patients (≥70 years), for those with a limited functioning performance at presentation (Karnofsky Performance Scale ≤70) or for those with tumours in certain locations (midline, multifocal). Therefore, the decision between resection and biopsy is varied, among neurosurgeons internationally and at times even within an institution. This study aims to compare the effects of maximal tumour resection versus tissue biopsy on survival, functional, neurological and quality of life outcomes in these patient subgroups.

View Article and Find Full Text PDF

Differentiation between multifocal CNS lymphoma and glioblastoma based on MRI criteria.

Discov Oncol

September 2024

Department of Neurosurgery, University Medical Center, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany.

Purpose: Differentiating between glioblastoma (GB) with multiple foci (mGB) and multifocal central nervous system lymphoma (mCNSL) can be challenging because these cancers share several features at first appearance on magnetic resonance imaging (MRI). The aim of this study was to explore morphological differences in MRI findings for mGB versus mCNSL and to develop an interpretation algorithm with high diagnostic accuracy.

Methods: In this retrospective study, MRI characteristics were compared between 50 patients with mGB and 50 patients with mCNSL treated between 2015 and 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!